Who is sponsoring NCT06655896?

NCT06655896 is sponsored by Novartis Pharmaceuticals.

What condition does NCT06655896 study?

NCT06655896 studies Scleroderma, Diffuse.

What drugs are being tested in NCT06655896?

Interventions: rapcabtagene autoleucel, rituximab.

What is the status of NCT06655896?

NCT06655896 is currently RECRUITING.

Last reviewed 2026-02-20 · How we verify

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896 PHASE2 RECRUITING

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	RECRUITING
Enrolment	96
Start date	Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Scleroderma, Diffuse

Interventions

rapcabtagene autoleucel
rituximab

Countries

Brazil, Israel, France, Czechia, Germany, United States, Italy, Taiwan, Hungary, South Korea, Singapore, Switzerland, Austria, Spain, Denmark, Australia, Netherlands, United Kingdom, Japan, Belgium